Akebia Therapeutics(AKBA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights • Vafseo (vadadustat) Tablets market availability on track for January 2025 • TDAPA application submission and WAC pricing announcement for Vafseo complete • Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 million ® Akebia to host conference call at 8:00 a.m. ET on August 8 CAMBRIDGE, Mass.—Aug 8, 2024—Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company ...